Nemorubicin hydrochloride (PNU-152243A) administered via intrahepatic artery in combination with cisplatin in adult patients with unresectable hepatocellular carcinoma: Phase II study preceded by dose-escalation.

Trial Profile

Nemorubicin hydrochloride (PNU-152243A) administered via intrahepatic artery in combination with cisplatin in adult patients with unresectable hepatocellular carcinoma: Phase II study preceded by dose-escalation.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2012

At a glance

  • Drugs Nemorubicin (Primary) ; Cisplatin
  • Indications Liver cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Nerviano Medical Sciences
  • Most Recent Events

    • 21 Jul 2012 Planned number of patients changed from 120 to 125 as reported in the European Clinical Trials Database record.
    • 21 Jul 2012 Planned end date changed from 28 Mar 2009 to 28 Mar 2008 as reported in the European Clinical Trials Database record.
    • 21 Jul 2012 Hospira added as associations as reported in the European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top